← Trials/Trial dossier/NCT02473809

LIRABONE

CompletedPhase 4

The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function

Lead sponsor

University of Aarhus

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Collagen I cross-linked C-terminal telopeptide measured in serum

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02473809

Org study ID07052015

Timeline

Milestones

Study first posted2015-06-17estimated

Last update posted2018-09-26actual

Study start2015-08 (month precision)

Primary completion2017-10actual (month precision)

Study completion2017-10actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age30 Years

Maximum age90 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Informed consent

•Diagnosis of type 2 diabetes (HbA1c > 48 mmol/mol)

•Age older than 30 years

Exclusion criteria

•Type 1 diabetes

•Treatment with insulin

•Body weight > 140 kg

•HbA1c > 75 mmol/mol

•Treatment with GLP-1 analogues, Dipeptidyl peptidase-4 inhibitors, or glitazones

•Chronic kidney disease

•Hepatic disease

•Pancreatitis

•Inflammatory bowel disease

•Osteoporosis

•Family or personal history of medullary thyroid carcinoma

•Treatment with glucocorticoids

•Hormone replacement therapy

•Diabetic gastroparesis

•Pregnancy or lactation

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Other clinical outcomes

Weight & body composition

Glycemic / diabetes

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Change in BMD evaluated by DXA

Time frame:Days 0, 90, 180

change from baseline, improvement

Glycemic / diabetes

1 endpoint

Secondary/protocol endpoint

Change in HbA1c

Time frame:Days 0, 180

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Other clinical outcomes

2 endpoints

Primary/protocol endpoint

Change in collagen I cross-linked C-terminal telopeptide measured in serum

Time frame:Days 0, 7, 28, 90, 180

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in bone structure evaluated by QCT and HRpQCT

Time frame:Days 0, 90, 180

change from baseline, improvement

Other (unclassified)

3 endpoints

Secondary/protocol endpoint/low confidence

Change in bone alkaline phosphatase measured in serum

Time frame:Days 0, 7, 28, 90, 180

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Change in osteocalcin measured in serum

Time frame:Days 0, 7, 28, 90, 180

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in procollagen type I N-terminal propeptide measured in serum

Time frame:Days 0, 7, 28, 90, 180

change from baseline, improvement

Publications (7)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.
Endocrine2015 Feb (month)PMID25074632doi:10.1007/s12020-014-0361-4via CT.gov background
Type 2 diabetes and bone.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2012 Nov (month)PMID23023946doi:10.1002/jbmr.1759via CT.gov background
GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia.
The Journal of endocrinology2011 May (month)PMID21372151doi:10.1530/JOE-11-0015via CT.gov background
The murine glucagon-like peptide-1 receptor is essential for control of bone resorption.
Endocrinology2008 Feb (month)PMID18039776doi:10.1210/en.2007-1292via CT.gov background
Diabetes, fracture, and bone fragility.
Current osteoporosis reports2007 Sep (month)PMID17925191doi:10.1007/s11914-007-0025-xvia CT.gov background
Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2007 Apr (month)PMID17068657doi:10.1007/s00198-006-0253-4via CT.gov background
The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets.
Pancreas1995 Aug (month)PMID7479679doi:10.1097/00006676-199508000-00014via CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.